Stevanato, currently a board director and the company’s executive chair, succeeds Franco Moro in the corner office. Moro’s employment agreement continues through June 30, 2024, after which he will remain on the company’s board.
This marks Stevanato’s second stint as the CEO at Stevanato Group, a Piombino Dese, Italy-based drug delivery device maker.
“On behalf of the board of directors and the company, I would like to express my sincere gratitude to Mr. Moro for his valuable contributions to Stevanato Group,” Stevanato said in a news release. “Over the last five years, Franco has played a pivotal role in helping to guide the Company through the challenges of the global COVID-19 pandemic, expand our global industrial footprint to meet rising customer demand, and drive global standardization of our manufacturing sites to improve operational efficiencies.”
Stevanato held the post of executive chair beginning in 2021. Before that, he served as CEO of Stevanato Group from 1998 to 2021. Over the past two decades, his track record includes leading long-term strategic vision and integrated value proposition. He led the company’s global expansion as well, enhanced R&D and expanded its product portfolio.
“We thank Franco Moro for his dedicated service to the company as chief executive officer. Looking ahead, Franco Stevanato is a strategic leader who has navigated the company through periods of growth and investment. He embodies the core principles and values of Stevanato Group, and the board is confident that Franco Stevanato is well positioned to advance the company’s strategic imperatives and drive long-term shareholder value,” said Fabrizio Bonnani, Stevanato Group’s lead independent director.
